Regulatory Filings • Feb 28, 2022
Regulatory Filings
Open in ViewerOpens in native device viewer
Photocure Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model
Press release - Oslo, Norway, 28 February 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the publication of new results from its
exploratory research program in the journal Biomedicines, entitled "Antitumor
Effect and Induced Immune Response Following Exposure of Hexaminolevulinate
(HAL) and Blue Light in an Orthotopic Model of Rat Bladder Cancer". These
results support initial pre-clinical data on the potential anti-tumor effect of
HAL, which were presented at the BLADDR 2019 congress
[https://photocure.com/news/photocure-new-data-from-hexvixr-trials-presented-at
-the-bladdr-2019-congress-3457632].
The study objective was based on the hypothesis that the positive impact on long
-term outcomes in NMIBC patients who had undergone Blue Light Cystoscopy (BLC)
prior to cystectomy could be caused by a direct anti-tumor effect and/or
activation of the immune system indicating an additional effect of Blue Light
with HAL beyond pure detection. Therefore, as an exploratory preclinical study,
the authors investigated whether intravesical administration of HAL followed by
a diagnostic blue-light illumination-regime, aiming to mimic the one used
currently in Photodynamic Diagnosis (PDD), could have anti-tumor and/or immune
modulating effects as seen with Photodynamic therapy (PDT). In addition, it was
explored if co-administration of a checkpoint inhibitor would increase the
susceptibility to the PD-1/PD-L1 pathway inhibition thus increasing the anti
-tumor effect. Over the years, Photocure has conducted a number of experiments
on "mechanisms of actions" effects of HAL, as well as to see if there
potentially are similar anti-tumor and immune modulating effects of PDD with
blue light as reported with PDT. For this study, rats were treated with HAL and
blue light in an orthotopic model of bladder cancer, and then subjected to
histopathological analysis of the bladder samples and additional assessment of
immune markers. Co-administration of HAL and blue light with a checkpoint
inhibitor was further evaluated in this model aiming to assess for potentiation
of anti-tumor effects when combined with an immunotherapy.
Results of the study demonstrated an anti-tumor effect of HAL and blue light
when aiming to mimic the dosing regimen of a photodynamic diagnostic procedure
(PDD) in an orthotopic bladder cancer model in rats.
The authors conclude "The anti-tumor effect is most probably pertaining to
stimulation of the immune system as evident by tumor infiltration of CD3+ and
CD8+ T-cells. These results support our hypothesis that the positive impact on
patient outcomes observed in patients who had undergone BLC prior to cystectomy
could be explained by systemic immune activation induced by HAL and blue light.
Combination of HAL and blue light with intravesical anti-PD-L1 resulted in
increased anti-tumor effects. Further studies are warranted to explore the long
-term effects of HAL and blue light alone or in combination with checkpoint
inhibitors which should extend to investigate any systemic (abscopal) effects.
Intriguingly is also the idea that local treatment with HAL and blue light can
prime an immune response with potential additional effect of checkpoint
inhibitors."
"The intriguing results from this pre-clinical study are encouraging and might
explain an effect of HAL+BL beyond pure detection. The results motivate further
research to evaluate the potential of HAL as a photodynamic therapy (PDT), which
may be an innovative technique for treatment of non-muscle invasive bladder
cancer.", said Anders Neijber, Vice President, Global Medical Affairs and
Clinical Development at Photocure.
Read the full article here: https://www.mdpi.com/2227-9059/10/3/548
Note to editors
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide, with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.
Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
https://photocure.com/partners/our-partners for further information on our
commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: [email protected]
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.